TORONTO, Aug. 8 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced senior management appointments, effective immediately. Dr. Alan M. Ezrin, Ph.D., has been promoted to Chief Executive Officer from his previous position as Chief Operating Officer. Brian Brohman, Chief Financial Officer, has taken on the additional role of Chief Business Officer.
“Dr. Ezrin’s more than 25 years of experience in research and business development in both the pharmaceutical and biotechnology sectors has enhanced Bradmer’s management capabilities since he joined our team a year ago,” said Dr. Mark C. Rogers, Executive Chairman. “Alan’s promotion was a natural step for Bradmer as we increase our clinical focus with the initiation of our multicenter Phase III trial for Neuradiab targeted for later this year. Alan’s experience, leadership and extensive knowledge of the biopharmaceutical industry combined with his expertise in executing sophisticated clinical trials on schedule and within budget will be invaluable to Bradmer.”
“Mr. Brohman’s promotion to Chief Business Officer recognizes his additional responsibilities with respect to licensing and business development opportunities,” said Dr. Alan Ezrin, Chief Executive Officer of Bradmer. “As we enter a pivotal stage in our development, Brian’s wealth of knowledge and ability to identify growth prospects is a perfect complement to the dynamic management team we have established.”
Dr. Mark C. Rogers, previously Chief Executive Officer will now hold the title Executive Chairman.
About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)
Bradmer Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new and innovative cancer therapies. Bradmer’s lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. To date, over US$60 million in grants and related support has driven research and development of the licensed treatment, which has been delivered to over 200 patients with promising results and has completed Phase II clinical trials at Duke University. Bradmer is currently in the process of organizing a pivotal multi-center clinical trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency.
Bradmer Pharmaceuticals Inc.'s common shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company’s current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting.
Bradmer Pharmaceuticals Inc.
CONTACT: Bradmer Pharmaceuticals Inc., Mr. Brian Brohman, Chief Businessand Financial Officer, Phone: (416) 361-6058 (Ext. 804), E-mail:bbrohman@bradmerpharma.com, Internet: www.bradmerpharma.com; InvestorRelations, Ross Marshall, The Equicom Group Inc., Phone: (416) 815-0700(Ext. 238), Fax: (416) 815-0080, E-mail: rmarshall@equicomgroup.com
